Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on target and HLA expression
INDs for TSC-204-A0201 and TSC-204-C0702 introduce the first two TCRs into TScan’s ImmunoBank, targeting MAGE-A1 on HLA types A*02:01 and C*07:02, respectively
https://finance.yahoo.com/news/tscan-therapeutics-announces-fda-clearance-120000100.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.